| Name | CD532 |
| Description | CD532 is A highly potent Aurora A kinase inhibitor with an IC50 value of 45 nM. CD532 can block Aurora A kinase activity, drive MYCN degradation, and can directly interact with AURKA and induce global conformational transformation. CD532 can be used to study cancer. |
| In vitro | In MYCN-amplified neuroblastoma cell lines SK-N-BE(2) and Kelly, CD532 (1-10000 nM; 72 h) exhibits cytotoxicity with EC50s of 223.2 nM and 146.7 nM, respectively[1].
In SK-N-BE(2) cells, CD532 (0.1-1 μM; 24 h) causes a dose-dependent loss of MYCN protein[1].
Furthermore, CD532 (1 μM; 6 h) prevents S-phase entry in SK-N-BE(2) cells[1]. |
| In vivo | In mice with subcutaneous sonic hedgehog (SHH)-subtype medulloblastoma, CD532 (25 mg/kg; i.p. twice weekly for 3 weeks) decreases the tumor volume and increases survival[1].
In MYCN-amplified neuroblastoma xenografts, CD532 (60 mg/kg; i.p. for 2 days) reduces the level of MYCN protein[1].
CD532 (20 mg/kg; i.p.) in mice exhibits a serum half-life of ~1.5 hours and an AUC0-24 of 27 μM•h[1]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 5 mg/mL (9.57 mM), Sonication is recommended.
DMSO : 150 mg/mL (287.07 mM), Sonication is recommended.
|
| Keywords | CD-532 | CD532 | CD 532 | AuroraKinase | Aurora Kinase | Aurora A |
| Inhibitors Related | Palmatine chloride | 6K465 | URMC-099 | MK-8745 | SC-514 | MBM-55S | SP600125 | KW-2449 | TAK-901 | Alisertib | CCT129202 | TCS7010 |
| Related Compound Libraries | Bioactive Compound Library | Epigenetics Compound Library | Kinase Inhibitor Library | Post-Translational Modification Compound Library | Inhibitor Library | Bioactive Compounds Library Max | Fluorochemical Library | Cell Cycle Compound Library | Anti-Cancer Compound Library |
United States
